Novo Nordisk A/S

NYSE:NVO Lagerbericht

Marktkapitalisierung: US$495.1b

Novo Nordisk Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Novo Nordisk is forecast to grow earnings and revenue by 14.4% and 13.1% per annum respectively. EPS is expected to grow by 14.9% per annum. Return on equity is forecast to be 87.2% in 3 years.

Wichtige Informationen

14.4%

Wachstumsrate der Gewinne

14.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum23.7%
Wachstumsrate der Einnahmen13.1%
Zukünftige Eigenkapitalrendite87.2%
Analystenabdeckung

Good

Zuletzt aktualisiert04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued

Oct 21

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Aug 07

Novo Nordisk: Better Buying Opportunities Ahead

Jul 26

Novo Nordisk: Buy On Dips

Jul 04

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Jun 26

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Jun 18

Novo Nordisk: Considerable Growth Beyond Ozempic

May 27

The FTC Cracks Down On Novo Nordisk's Ozempic

May 03

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Apr 26

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Mar 07

Novo Nordisk, A Very Healthy Pharma Stalwart

Feb 28

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Gewinn- und Umsatzwachstumsprognosen

NYSE:NVO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (DKK Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2026402,839148,574116,943162,76120
12/31/2025345,150126,02594,471140,14824
12/31/2024287,496101,22171,975122,75724
6/30/2024258,00389,89866,027115,334N/A
3/31/2024244,24389,27650,30493,408N/A
12/31/2023232,26183,68370,012108,908N/A
9/30/2023214,49075,31277,825106,458N/A
6/30/2023201,32567,23967,49789,731N/A
3/31/2023188,29061,12967,34185,115N/A
12/31/2022176,95455,52564,13478,887N/A
9/30/2022167,19552,82557,87568,769N/A
6/30/2022157,25150,53957,68066,037N/A
3/31/2022149,02749,34459,66567,331N/A
12/31/2021140,80047,75747,61555,000N/A
9/30/2021134,60546,18340,21358,189N/A
6/30/2021129,91044,36231,81454,188N/A
3/31/2021126,87542,86431,33753,194N/A
12/31/2020126,94642,13829,87051,951N/A
9/30/2020127,22541,53744,80056,944N/A
6/30/2020126,57541,43347,62156,126N/A
3/31/2020126,60540,40336,98746,904N/A
12/31/2019122,02138,95135,55146,782N/A
9/30/2019119,33638,73136,78549,029N/A
6/30/2019116,82137,57431,25143,960N/A
3/31/2019114,19238,32232,20244,691N/A
12/31/2018111,83138,62832,20644,616N/A
9/30/2018110,09138,38431,57643,236N/A
6/30/2018108,94339,11733,78744,538N/A
3/31/2018110,17438,725N/A38,885N/A
12/31/2017111,69638,130N/A41,168N/A
9/30/2017113,27638,576N/A46,289N/A
6/30/2017114,19938,609N/A48,557N/A
3/31/2017113,02038,626N/A52,937N/A
12/31/2016111,78037,925N/A48,314N/A
9/30/2016111,08437,484N/A47,280N/A
6/30/2016110,33936,064N/A44,179N/A
3/31/2016109,93934,439N/A41,656N/A
12/31/2015107,92734,860N/A38,287N/A
9/30/2015103,63633,131N/A35,469N/A
6/30/201599,09331,248N/A35,578N/A
3/31/201593,66329,899N/A31,729N/A
12/31/201488,80626,481N/A31,692N/A
9/30/201485,91926,005N/A29,763N/A
6/30/201484,18125,920N/A23,783N/A
3/31/201483,93225,660N/A22,941N/A
12/31/201383,57225,184N/A25,942N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NVO's forecast earnings growth (14.4% per year) is above the savings rate (2.5%).

Ertrag vs. Markt: NVO's earnings (14.4% per year) are forecast to grow slower than the US market (15.4% per year).

Hohe Wachstumserträge: NVO's earnings are forecast to grow, but not significantly.

Einnahmen vs. Markt: NVO's revenue (13.1% per year) is forecast to grow faster than the US market (8.9% per year).

Hohe Wachstumseinnahmen: NVO's revenue (13.1% per year) is forecast to grow slower than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NVO's Return on Equity is forecast to be very high in 3 years time (87.2%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y